Advertisement

Vitiligo pp 411-420 | Cite as

Combined/Sequential/Integrated Therapies for Vitiligo

  • Thierry PasseronEmail author
Chapter

Abstract

Vitiligo is a challenging disorder to treat, and to date no treatment provides truly satisfactory results. However, from molecules that target the immune system to therapies that stimulate the proliferation and differentiation of melanocytes and/or melanocyte progenitors and others that fight against radical species or bring new melanocytes to the affected areas, we have many strategies to repigment vitiligo patches. Association of surgical procedures with phototherapy was the first to demonstrate that combination approaches could further increase repigmentation rates. The interest of combining medical approaches is now also well demonstrated in several prospective randomized studies. This is mainly true for the association of topical treatments, such as calcineurin inhibitor or topical corticosteroids, with phototherapy. Other interesting associations are those between antioxidants and lasers, but the data remain limited. New strategies have been also reported aiming to reduce the risk of relapse after achieving repigmentation. The development in the near future of targeted immune treatments but also new topical drugs aiming to enhance the differentiation of melanocyte stem cells should lead to new and hopefully more effective combination or sequential protocols adapted to the severity and the activity of each vitiligo.

References

  1. 1.
    Bonafe JL, Lassere J, Chavoin JP, et al. Pigmentation induced in vitiligo by normal skin grafts and PUVA stimulation: a preliminary study. Dermatologica. 1983;166:113–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Barman KD, Khaitan BK, Verma KK. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg. 2004;30:49–53.PubMedGoogle Scholar
  3. 3.
    Hann SK, Im S, Bong HW, et al. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol. 1995;32:943–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Hann SK, Im S, Park YK, et al. Repigmentation of leukotrichia by epidermal grafting and systemic psoralen plus UV-A. Arch Dermatol. 1992;128:998–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee AY, Jang JH. Autologous epidermal grafting with PUVA-irradiated donor skin for the treatment of vitiligo. Int J Dermatol. 1998;37:551–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Shenoi SD, Srinivas CR, Pai S. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol. 1997;36:802–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Skouge J, Morison WL. Vitiligo treatment with a combination of PUVA therapy and epidermal autografts. Arch Dermatol. 1995;131:1257–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Skouge JW, Morison WL, Diwan RV, et al. Autografting and PUVA. A combination therapy for vitiligo. J Dermatol Surg Oncol. 1992;18:357–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Suga Y, Butt KI, Takimoto R, et al. Successful treatment of vitiligo with PUVA-pigmented autologous epidermal grafting. Int J Dermatol. 1996;35:518–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Tsukamoto K, Osada A, Kitamura R, et al. Approaches to repigmentation of vitiligo skin: new treatment with ultrasonic abrasion, seed-grafting and psoralen plus ultraviolet A therapy. Pigment Cell Res. 2002;15:331–4.PubMedCrossRefGoogle Scholar
  11. 11.
    van Geel N, Ongenae K, De Mil M, et al. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol. 2004;140:1203–8.PubMedGoogle Scholar
  12. 12.
    Lahiri K, Malakar S, Sarma N, et al. Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)--a prospective study. Int J Dermatol. 2006;45:649–55.PubMedCrossRefGoogle Scholar
  13. 13.
    Pianigiani E, Risulo M, Andreassi A, et al. Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. Dermatol Surg. 2005;31:155–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Linthorst Homan MW, Spuls PI, Nieuweboer-Krobotova L, et al. A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. J Eur Acad Dermatol Venereol. 2012;26:690–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Lahiri K, Malakar S, Sarma N, et al. Inducing repigmentation by regrafting and phototherapy (311 nm) in punch grafting failure cases of lip vitiligo: a pilot study. Indian J Dermatol Venereol Leprol. 2004;70:156–8.PubMedGoogle Scholar
  16. 16.
    Lee KJ, Choi YL, Kim JA, et al. Combination therapy of epidermal graft and systemic corticosteroid for vitiligo. Dermatol Surg. 2007;33:1002–3.PubMedGoogle Scholar
  17. 17.
    Mulekar SV. Stable vitiligo treated by a combination of low-dose oral pulse betamethasone and autologous, noncultured melanocyte-keratinocyte cell transplantation. Dermatol Surg. 2006;32:536–41.PubMedGoogle Scholar
  18. 18.
    Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999;135:1061–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol. 2008;159:1186–91.PubMedGoogle Scholar
  20. 20.
    Bae JM, Hong BY, Lee JH, et al. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016;74:907–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Li R, Qiao M, Wang X, et al. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. Photodermatol Photoimmunol Photomed. 2017;33(1):22–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47:789–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology (Basel, Switzerland). 2002;205:301–3.CrossRefGoogle Scholar
  25. 25.
    Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis. 2003;71:158–62.PubMedGoogle Scholar
  26. 26.
    Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol. 2003;139:571–4; discussion 3.PubMedCrossRefGoogle Scholar
  27. 27.
    Ostovari N, Passeron T, Lacour JP, et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol. 2006;142:252–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004;140:1065–9.PubMedGoogle Scholar
  29. 29.
    Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004;30:130–5.PubMedGoogle Scholar
  30. 30.
    Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed. 2003;19:35–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20:14–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Fai D, Cassano N, Vena GA. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol. 2007;21:916–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Stinco G, Piccirillo F, Forcione M, et al. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol. 2009;19:588–93.PubMedGoogle Scholar
  34. 34.
    Tanghetti EA, Gillis PR. Clinical evaluation of B Clear and Protopic treatment for vitiligo. Lasers Surg Med. 2003;32:37.Google Scholar
  35. 35.
    Dayal S, Sahu P, Gupta N. Treatment of childhood vitiligo using tacrolimus ointment with narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2016;33(6):646–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Hui-Lan Y, Xiao-Yan H, Jian-Yong F, et al. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol. 2009;26:354–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Dang YP, Li Q, Shi F, et al. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016;29:126–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Tran C, Lübbe J, Sorg O, Doelker L, Carraux P, Antille C, Grand D, Leemans E, Kaya G, Saurat JH. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology. 2005;211(4):341–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol. 2002;16:137–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21:79–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Anke Hartmann CL, Hamm H, Bröcker E-B, Hofmann UB. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. 2004;44(9):736–42.CrossRefGoogle Scholar
  43. 43.
    Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol. 2006;33:338–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Baysal V, Yildirim M, Erel A, et al. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol. 2003;17:299–302.PubMedCrossRefGoogle Scholar
  45. 45.
    Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol. 2001;145:472–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20:553–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007;21:504–8.PubMedGoogle Scholar
  48. 48.
    Khullar G, Kanwar AJ, Singh S, et al. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015;29:925–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2004;20:248–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Leone G, Pacifico A, Iacovelli P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006;31:200–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Lu-yan T, Wen-wen F, Lei-hong X, et al. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2006;22:310–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Oh SH, Kim T, Jee H, et al. Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. J Am Acad Dermatol. 2011;65:428–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology (Basel Switzerland). 1998;197:167–70.CrossRefGoogle Scholar
  54. 54.
    Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology (Basel, Switzerland). 1995;190:223–9.CrossRefGoogle Scholar
  55. 55.
    Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol. 2002;27:641–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol. 2009;161:910–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Dell’Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Anbar TS, Westerhof W, Abdel-Rahman AT, et al. Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short-term NB-UVB phototherapy in the treatment of non-segmental vitiligo: a left-right comparative study. Photodermatol Photoimmunol Photomed. 2008;24:322–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Bayoumi W, Fontas E, Sillard L, et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol. 2012;166:208–11.PubMedCrossRefGoogle Scholar
  61. 61.
    Shin J, Lee JS, Hann SK, et al. Combination treatment by 10 600 nm ablative fractional carbon dioxide laser and narrowband ultraviolet B in refractory nonsegmental vitiligo: a prospective, randomized half-body comparative study. Br J Dermatol. 2012;166:658–61.PubMedCrossRefGoogle Scholar
  62. 62.
    Helou J, Maatouk I, Obeid G, et al. Fractional laser for vitiligo treated by 10,600 nm ablative fractional carbon dioxide laser followed by sun exposure. Lasers Surg Med. 2014;46:443–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Vachiramon V, Chaiyabutr C, Rattanaumpawan P, et al. Effects of a preceding fractional carbon dioxide laser on the outcome of combined local narrowband ultraviolet B and topical steroids in patients with vitiligo in difficult-to-treat areas. Lasers Surg Med. 2016;48:197–202.PubMedCrossRefGoogle Scholar
  64. 64.
    Li L, Wu Y, Sun Y, et al. Triple combination treatment with fractional CO2 laser plus topical betamethasone solution and narrowband ultraviolet B for refractory vitiligo: a prospective, randomized half-body, comparative study. Dermatol Ther. 2015;28:131–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Regazzetti C, Alcor D, Chignon-Sicard B, et al. Micro holes for delivering melanocytes into the skin: an ex vivo approach. Pigment Cell Melanoma Res. 2016;29:481–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Silpa-Archa N, Griffith JL, Williams MS, et al. Prospective comparison of recipient-site preparation with fractional carbon dioxide laser vs. dermabrasion and recipient-site dressing composition in melanocyte-keratinocyte transplantation procedure in vitiligo: a preliminary study. Br J Dermatol. 2016;174:895–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Nicolaidou E, Antoniou C, Stratigos AJ, et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Schmitt J, von Kobyletzki L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164:415–28.PubMedCrossRefGoogle Scholar
  69. 69.
    Cavalie M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223ra23.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J Invest Dermatol. 2015;135:3105–14.PubMedCrossRefGoogle Scholar
  72. 72.
    Richmond JM, Bangari DS, Essien KI, et al. Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol. 2016;137(2):350–8.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Wang XX, Wang QQ, Wu JQ, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174:1318–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University Côte d’Azur, Department of DermatologyUniversity Hospital of NiceNice Cedex 3France
  2. 2.University Côte d’Azur, INSERM U1065, team 12, C3MNiceFrance

Personalised recommendations